

Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BIIB | NASDAQ | USD | Real-time | |
0R1B | London | USD | Real-time | |
1BIIB | Milan | EUR | Real-time | |
BIIB | Frankfurt | EUR | Delayed | |
BIIB | TradeGate | EUR | Delayed | |
BIIB | Xetra | EUR | Delayed | |
BIIB | Santiago | USD | Delayed | |
BIIBm | Buenos Aires | ARS | Delayed | |
BIIB34 | B3 | BRL | Delayed | |
BIIB | Vienna | EUR | Real-time |
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of amyotrophic lateral sclerosis; FUMADERM for the treatment of plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Christopher A. Viehbacher | 62 | 2022 | President, CEO & Director |
Caroline D. Dorsa | 64 | 2010 | Independent Chair of the Board |
Maria C. Freire | 69 | 2021 | Independent Director |
Eric K. Rowinsky | 66 | 2010 | Independent Director |
Stephen A. Sherwin | 74 | 2010 | Independent Director |
Jesus B. Mantas | 54 | 2019 | Independent Director |
William A. Hawkins | 69 | 2019 | Independent Director |
Monish D. Patolawala | 52 | 2024 | Independent Director |
Susan Langer | 32 | 2023 | Independent Director |
Lloyd B. Minor | - | 2024 | Directors |
Menelas Nicolas Pangalos | 57 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review